Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03536754 · ClinicalTrials.gov registry record · Phase 2
A Study of CCX140-B in Subjects With FSGS
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT03536754 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 46 participants.
The verdict
NCT03536754, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia
Interventions
- OTHER Placebo
- DRUG CCX140-B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-05-17 |
| Est. Completion | 2020-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03536754
The ClinicalTrials.gov registry entry for NCT03536754 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03536754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03536754 about?
NCT03536754 is a clinical study titled "A Study of CCX140-B in Subjects With FSGS". A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia
What is the current status of trial NCT03536754?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2018-05-17. Estimated completion is 2020-02-19.
What interventions are being tested in trial NCT03536754?
The interventions under investigation include: Placebo (OTHER), CCX140-B (DRUG).
Who is sponsoring clinical trial NCT03536754?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.